Get started

Financials · ABEO

Abeona Therapeutics Inc. (ABEO) financials

For the twelve months ended Sep 30, 2026, Abeona Therapeutics Inc. reported $39.01M of revenue and -$62.53M of net income.

Revenue, TTM
$39.01M
Revenue growth, YoY
+785.6%
Net income, TTM
-$62.53M
Net margin
-160.3%
Free cash flow, TTM
-$66.35M
Cash
$66.28M
Total debt
$11.85M
P/S
3.72
Market cap
$145.2M
Annual revenue$5.82M
FY2016FY2025
Annual net income$71.18M
FY2016FY2025
Annual free cash flow-$84.30M
FY2016FY2025

ABEO revenue and earnings growth

ABEO revenueQ3 2026$13.49M

Quarter YoY
+706.9%
QoQ
+18.6%
FY YoY
+37.1%
5Y CAGR
-10.3%
10Y CAGR
+18.8%

ABEO revenue was $13.49M in fiscal Q3 2026 (ended Sep 30, 2026), up 706.9% from a year earlier and up 18.6% from the prior quarter. For the full fiscal 2025 it was $5.82M, up 37.1% from fiscal 2024. Compound annual growth was -10.3% over 5 years and +18.8% over 10 years. It rose in 3 of the last 5 fiscal years.

ABEO net incomeQ3 2026-$4.81M

ABEO net income was -$4.81M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$5.16M a year earlier. For the full fiscal 2025 it was $71.18M, compared with -$63.73M in fiscal 2024. Fiscal 2025 is the highest of the 15 fiscal years on file.

ABEO EPSQ3 2026-$0.08

ABEO diluted EPS was -$0.08 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.10 a year earlier. For the full fiscal 2025 it was $1.01.

ABEO free cash flowQ3 2026-$8.53M

ABEO free cash flow was -$8.53M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$23.71M a year earlier. For the full fiscal 2025 it was -$84.30M, compared with -$58.46M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$5.82M$4.25M$3.50M$1.41M$3.00M$10.00M-$3.00M$837.0K$889.0K
Cost of revenue$1.53M---------
Gross profit$4.29M---------
Research and development$26.81M$34.36M$31.09M$28.96M$38.73M$30.14M$48.57M$38.70M$16.99M$10.65M
Selling, general and admin$65.03M$29.85M$19.00M$17.26M$21.64M$23.78M$20.70M$20.11M$10.94M$13.29M
Operating income-$89.45M-$64.21M-$47.13M-$50.91M-$89.84M-$81.42M-$77.09M-$58.17M-$27.84M-$23.88M
Interest expense$3.74M$4.21M$418.0K$736.0K$3.66M$4.12M----
Pre-tax income$71.28M-$63.73M--------
Income tax$100.0K------$0$0$0
Net income$71.18M-$63.73M-$54.19M-$39.70M-$84.94M-$84.23M-$76.28M-$56.67M-$27.32M-$21.87M
EPS, basic$1.34-$1.55-$2.53-$5.53-$21.57-$0.91-$1.51-$1.19-$0.66-$0.64
EPS, diluted$1.01-$1.55-$2.53-$5.53-$0.86-$0.91-$1.51-$1.19-$0.66-$0.64
Diluted shares66.1M41.0M21.4M7.9M98.4M92.7M50.4M47.5M41.6M34.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$78.44M$23.36M$14.47M$14.22M$32.94M$12.60M$129.26M$18.75M$137.75M$69.14M
Short-term investments$112.97M$74.36M$37.75M$37.93M$12.09M$82.44M-$66.22M$0-
Receivables$6.15M---$3.00M--$81.0K$107.0K$124.0K
Inventory$5.49M---------
Current assets$204.91M$100.85M$55.74M$53.10M$56.29M$97.74M$132.39M$88.85M$140.59M$69.42M
Goodwill-----$32.47M$32.47M$32.47M$32.47M$32.47M
Total assets$219.57M$108.93M$64.00M$64.21M$79.59M$151.20M$223.38M$174.40M$178.77M$111.06M
Current liabilities$29.57M$16.59M$13.42M$7.78M$16.62M$41.96M$38.70M$20.35M$5.61M$8.30M
Short-term debt$12.22M$5.93M--------
Long-term debt$7.81M$13.04M--------
Total debt$20.04M$18.96M--------
Total liabilities$60.35M$64.90M$49.18M$37.45M$37.22M$48.65M$44.95M$40.35M$8.67M$11.96M
Shareholders' equity$159.22M$44.03M$14.83M$26.76M$42.37M$102.55M$178.43M$134.04M$170.10M$99.10M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$76.33M-$56.02M-$37.01M-$43.48M-$65.67M-$35.02M-$62.82M-$39.11M-$22.66M-$13.01M
Capital expenditures$7.97M$2.45M$331.0K$130.0K$4.15M$1.34M$6.31M$9.24M$860.0K$519.0K
Free cash flow-$84.30M-$58.46M-$37.34M-$43.61M-$69.82M-$36.35M-$69.13M-$48.35M-$23.52M-$13.53M
Investing cash flow$105.03M-$39.24M$208.0K-$23.96M$66.06M-$83.71M$59.98M-$85.09M-$860.0K-$519.0K
Financing cash flow$26.04M$104.14M$37.06M$43.17M$24.86M$1.94M$113.90M$5.48M$92.40M$42.54M
Stock-based compensation$10.78M$6.63M$4.77M$3.05M------
Depreciation and amortization$2.55M$2.00M$2.29M$3.09M$3.25M$4.59M$7.82M$2.36M$741.0K$825.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY37.1%21.3%147.5%-52.9%-70.0%--258.2%-5.8%-14.5%
Gross margin73.7%---------
Operating margin-1536.9%-1512.3%-1346.7%-3600.8%-2994.5%-814.2%--1940.2%-3325.7%-2686.3%
Net margin1223.1%-1501.0%-1548.2%-2807.4%-2831.2%-842.3%--1890.3%-3263.9%-2460.4%
Free cash flow margin-1448.5%-1376.8%-1066.9%-3084.4%-2327.2%-363.6%--1612.9%-2809.4%-1522.3%
Return on equity44.7%-144.7%-365.5%-148.3%-200.5%-82.1%-42.8%-42.3%-16.1%-22.1%
Return on assets32.4%-58.5%-84.7%-61.8%-106.7%-55.7%-34.1%-32.5%-15.3%-19.7%
Current ratio6.936.084.156.833.392.333.424.3725.078.37
Debt to equity0.130.43--------

Source: XBRL data Abeona Therapeutics Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-50, first reported Nov 14, 2014.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ABEO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ABEO$39.01M+785.6%-$62.53M-160.3%$145.2M
KRYS$470.02M+26.0%$225.17M47.9%$8.98B
RCKT$0--$17.25M-$278.3M
RARE$730.00M+15.8%-$524.00M-71.8%$1.67B
RGNX$153.91M-4.6%-$175.23M-113.9%$533.6M
QURE$20.17M+28.0%-$232.90M-1154.8%$1.60B
SRPT$1.96B-18.9%-$114.62M-5.9%$1.85B

ABEO FAQ

8 questions
  • What is ABEO revenue?
    Abeona Therapeutics Inc. (ABEO) reported $39.01M of revenue for the twelve months ended Sep 30, 2026. That is up 785.6% from the year before. Revenue for fiscal 2025 was $5.82M.
  • Is ABEO profitable?
    No. Abeona Therapeutics Inc. reported a net loss of $62.53M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ABEO have?
    Abeona Therapeutics Inc. reported $66.28M in cash and cash equivalents and $11.85M of debt on its most recent balance sheet in SEC filings.
  • How fast is ABEO revenue growing?
    Abeona Therapeutics Inc.'s revenue changed +37.1% in fiscal 2025, to $5.82M. Its compound annual growth rate was -10.3% over 5 years and +18.8% over 10 years.
  • What is ABEO gross margin?
    Abeona Therapeutics Inc.'s gross profit was $25.38M on $39.01M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 65.1%.
  • What is ABEO free cash flow?
    Abeona Therapeutics Inc. generated -$66.35M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$63.56M less capital expenditures.
  • When did ABEO last report financial results?
    The latest statements here come from Abeona Therapeutics Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.
  • Where does this ABEO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Abeona Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.